A New Chapter for Avalo Therapeutics: Michael Heffernan Takes the Helm as Chairman of the Board
Wayne, PA and Rockville, MD, March 26, 2025 – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage biotechnology company committed to addressing immune dysregulation, recently announced some major changes in its executive leadership. Effective immediately, Michael Heffernan will assume the role of Chairman of the Board of Directors (BoD), replacing Dr. Garry Neil, who will continue serving as a valued Board member and the Company’s CEO.
Background on Michael Heffernan
Michael Heffernan brings a wealth of experience in the biotech and pharmaceutical industries to Avalo Therapeutics. He has spent over 30 years in various executive roles, including serving as the President and CEO of several publicly-traded companies. Heffernan’s extensive background in business development, strategic planning, and operational management will be invaluable in guiding Avalo Therapeutics through its next stages of growth.
Dr. Garry Neil’s Continued Commitment
Despite his new role as Chairman, Dr. Garry Neil remains dedicated to leading Avalo Therapeutics as its CEO. Neil has been a driving force behind the Company’s successes, including its recent clinical advancements and collaborations with leading research institutions. With Heffernan’s expertise in corporate leadership, Neil will be able to focus more on the scientific aspects of Avalo Therapeutics, ensuring the Company continues to deliver innovative solutions for immune dysregulation.
Impact on Avalo Therapeutics: A Fresh Perspective
The appointment of Michael Heffernan as Chairman of the Board marks an exciting new chapter for Avalo Therapeutics. With his extensive experience in the industry, Heffernan will bring a fresh perspective and strategic insights to the Company’s leadership. This change will enable Avalo Therapeutics to more effectively navigate the complex biotech landscape and capitalize on new opportunities.
Impact on the World: Advancing the Fight Against Immune Dysregulation
The biotech industry is constantly evolving, and the appointment of Michael Heffernan to the BoD at Avalo Therapeutics is a significant step forward in the fight against immune dysregulation. By bringing together the expertise of Heffernan and Neil, Avalo Therapeutics is better equipped to develop innovative treatments and collaborate with leading research institutions. This will ultimately lead to improved patient outcomes and a better understanding of the underlying causes of immune dysregulation.
Conclusion: A Stronger, More Dynamic Team
In conclusion, the appointment of Michael Heffernan as Chairman of the Board of Directors at Avalo Therapeutics is a testament to the Company’s commitment to addressing immune dysregulation and its dedication to building a strong, dynamic team. With the combined expertise of Heffernan and Neil, Avalo Therapeutics is poised to make a significant impact on the biotech industry and the lives of those affected by immune dysregulation.
- Avalo Therapeutics appoints Michael Heffernan as Chairman of the Board, replacing Dr. Garry Neil.
- Heffernan brings extensive experience in business development, strategic planning, and operational management.
- Dr. Garry Neil continues as CEO, focusing on scientific aspects of the Company.
- Heffernan’s appointment marks an exciting new chapter for Avalo Therapeutics.
- The change will enable Avalo Therapeutics to more effectively navigate the biotech landscape and capitalize on new opportunities.
- Avalo Therapeutics is better equipped to develop innovative treatments and collaborate with leading research institutions.
- The appointment will lead to improved patient outcomes and a better understanding of the underlying causes of immune dysregulation.
